BBLG BBLG
Company Profile ↓Company Overview
BBLG (BBLG) is a publicly traded company listed on with a market capitalization of $1.76M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue +0.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 0.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 0.00% |
| 1 Year: | 0.00% |
Stock Price Performance
| 1 Year: | -64.23% |
| 6 Months: | -37.97% |
| 3 Months: | -25.76% |
| 1 Month: | -33.33% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)37.11 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 65.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jan 2014 | Mar 2014 | Apr 2014 | Jun 2014 | Jul 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.07B | - | - | 1.07B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | - | -173.76K | - | -316.49K | - | -1.73M | -923.42K | -510.58K | -2.97M | -9.10M | -4.34M | -3.86M | -2.16M | 1.97M | -1.13M | -1.10M | -860.15K | 404.79K | -1.19M | -679.26K | -301.31K | -340.05K | -132.71K | -145.82K | -180.92K | -231.88K | -229.79K | -689.50K | -469.30K | -1.22M | -3.15M | -3.04M | -2.08M | -903.54K | -809.66K | -951.02K | -1.04M | -748.08K | -715.27K | -805.05K |
| Net Income | -1.98K | -323.65K | -1.78K | -427.57K | -1.31K | -2.61M | -1.64M | -890.80K | -3.36M | -12.26M | -4.70M | -4.22M | -2.92M | 1.02M | -2.38M | -1.45M | -1.26M | -241.74K | -1.41M | -925.55K | -561.42K | -596.90K | -380.03K | -394.05K | -431.75K | -491.90K | -509.30K | -689.50K | -469.30K | -1.22M | -3.71M | -1.77M | -1.92M | -865.97K | -783.73K | -941.00K | -1.02M | -740.52K | -666.74K | -765.99K |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | -0.13 | - | - | 0.25 | - | - | -0.29 | - | - | - | - | - | - | - | - | - | - | - | -1.36 | -3.53 | -55.20 | -5.21 | -4.90 | -1.31 | -4.02 | -14.21 | -1.92 | -1.33 | -0.37 | -0.43 |
| R&D Expense | - | 49.65K | - | 133.46K | - | 256.46K | 188.29K | 175.01K | 302.66K | 4.68M | 2.32M | 2.47M | 406.89K | 423.93K | 234.26K | 369.01K | 187.46K | -1.07M | 564.33K | 417.56K | 44.94K | 167.10K | 9.00K | 142.88K | 45.50K | 2.02K | - | 36.40K | 17.60K | 769.41K | 2.59M | 2.30M | 1.57M | 245.62K | 350.44K | 429.75K | 423.58K | 191.61K | 187.81K | 141.60K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Oct 2008 | Oct 2009 | Oct 2010 | Oct 2011 | Oct 2012 | Oct 2013 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 1.07B | 1.07B | - | - | - | - | - |
| Operating Income | - | - | - | - | - | - | -671.99K | -3.01M | -12.00M | -20.41M | -2.63M | -2.79M | -2.45M | -825.01K | -1.10M | -3.67M | -9.43M | -4.22M | -3.23M |
| Net Income | -13.34K | -10.29K | -3.60K | -4.92K | -5.63K | -5.21K | -1.08M | -4.42M | -13.88M | -25.88M | -7.05M | -4.43M | -3.42M | -1.82M | -1.61M | -1.48M | -8.95M | -4.11M | -3.11M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -31.15 | -34.01 | -28.96 | -2.65 |
| R&D Expense | - | - | - | - | - | - | 188.24K | 623.52K | 3.67M | 10.17M | 1.42M | 104.49K | 1.10M | 340.67K | 82.04K | 1.58M | 6.91M | 2.13M | 1.06M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Oct 2007 | Oct 2008 | Oct 2009 | Oct 2010 | Oct 2011 | Oct 2012 | Dec 2012 | Oct 2013 | Dec 2013 | Dec 2014 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | - | 0 | 500 | - | 380 | 87.31K | 3.82M | 1.55M | 4.32M | 2.33M | 771.39K | 701.14K | 1.70M | 868.39K | 1.67M | 795.66K | 1.04M | 30.83K | 0 | - | 8.50M | 3.74M | 3.86M | 5.80M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.50M | 3.74M | 3.86M | 5.80M |
| Cash & Equivalents | - | - | - | - | 0 | 500 | 2.37K | 380 | 1.54K | 2.66M | 1.12M | 4.22M | 2.19M | 688.23K | 620.38K | 1.61M | 783.01K | 1.62M | 690.28K | 955.37K | 24.14K | - | - | 7.54M | 3.03M | 3.33M | 5.33M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 579.91K | 328.84K | 0 | 9.89K |
| Total Liabilities | - | - | - | 24.05K | 28.97K | 35.10K | - | 40.19K | 5.70M | 7.52M | 7.23M | 7.55M | 7.71M | 7.73M | 9.06M | 9.54M | 10.54M | 11.85M | 9.19M | 9.64M | 11.90M | 13.69M | - | 2.55M | 831.40K | 377.71K | 418.59K |
| Current Liabilities | - | - | - | - | - | - | - | - | 5.70M | 3.87M | 2.15M | 484.01K | 481.70K | 335.62K | 1.50M | 1.81M | 2.68M | 3.82M | 961.79K | 9.64M | 578.45K | 13.69M | - | 2.55M | 831.40K | 377.71K | 418.59K |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Equity | -9.72K | -10.17K | -20.45K | -24.05K | -28.97K | -34.60K | -4.68M | -39.80K | -5.61M | -3.70M | -4.20M | -3.23M | -5.38M | -6.96M | -8.36M | -7.85M | -9.68M | -10.18M | -8.40M | -8.60M | -11.87M | -13.69M | - | 5.95M | 2.91M | 3.48M | 5.38M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.63K | 89.04K | 492.33K | 1.80M |
Cash Flows (Annual)
Figures in USD.
| Metric | Oct 2010 | Oct 2011 | Oct 2012 | Oct 2013 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -5.68K | -3.60K | -6.06K | -6.12K | -525.37K | -2.76M | -3.55M | -7.33M | -3.33M | -4.10M | -3.25M | -426.93K | -1.23M | -3.57M | -9.56M | -4.12M | -2.69M |
| Investing Cash Flow | - | - | - | - | - | 25.48K | -504 | - | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | 5.68K | 3.60K | 6.56K | 6.00K | 524.53K | 5.39M | 2.00M | 6.83M | 3.40M | 4.37M | 2.32M | 402.79K | 7.90M | 4.43M | 5.04M | 4.42M | 4.70M |
| Capital Expenditure | - | - | - | - | - | -11.90K | -504 | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | -2.77M | -3.55M | - | - | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Oct 2008 | Oct 2009 | Oct 2010 | Oct 2011 | Oct 2012 | Oct 2013 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | -0.2% | -0.1% | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | -0.3% | -0.2% | - | - | - | - | - |
| ROE % | 131.3% | 50.3% | 15.0% | 17.0% | 16.3% | 13.1% | 19.3% | 119.6% | 330.6% | 309.4% | 84.0% | 51.5% | 28.9% | 13.3% | - | -25.0% | -307.9% | -118.0% | -57.8% |
| ROCE % | - | - | - | - | - | - | 12.0% | 5,645.7% | 2,005.0% | 2,549.4% | 1,581.0% | 32.5% | 446.9% | 6.0% | - | -61.6% | -324.4% | -121.1% | -60.2% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BBLG
Price to earnings forward of Bone Biologics Corp – NASDAQ:BBLG - TradingView
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxNbVFWQlltTVN4SF9nNEViM1l6cXYweGF6eFd5M2NjWnRBaW5Vek5NcTFvcmlHNkxQM2VUUGRHRWthUUh3bl84NjF5Vzl3Y3JyRVhhQjRkM0EtV2tpcEdEWUR4cDNFOFRtVGhCVzZVTGJ0TmNYWE9jdXc0UklkS0lSVExpVFRJckR1VzJQTU…
Bone Biologics extends rhNELL-1 shelf life to 29 months - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxPcGlEbkpQX2xRSVcxSjZLUlJBUEhsNEVVYW81NlJUMXhvbGozNVFmVE5Kb0JfM1lfMDl3aGgyQkpLR0hNdjZQQ1RjektFS190cXlFMWpqWEs3QUJpRDZicjBaeEo0NXUteE1xQ2ZMMVVKaDFOSFJMbDh1dngyVXN6OE1JcEM2X1RiWmE0al…
BBLG | Bone Biologics Corp Common Insider Trading - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTE8tQUJfbzZGNzVWOXJvcWs0RGRZdkx4S2JLZm1hN0w4VjBQTHdFZXE0UWtsMk01TEgxYk80bkQyT1BCSGtXWFNVMzdmaU1DOExwWkY2WGVpMlNHZVRa?oc=5" target="_blank">BBLG | Bone Biologics Corp Common Insider T…
BBLG|Bone Biologics Corp|Price:0.925|Chg%:+0.071 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTFBLOVBrVHloNnYxWjlub00xaV9BOTJjZW9xRHZ6aEY3N2ZZTEdfaGktWTNGZ3NuemxmWGdMZDZTcmlrR2ExRi05MGhPSU5Gdm5yU1I1QTVKWExoWktaU1N6S0YxZlhUdUV5VkFiZUNR?oc=5" target="_blank">BBLG|Bone Biologics…
Bone Biologics Corp SEC Filing (Jul 27, 2026) - Stock Titan
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxPQlJYWHJoYm1jR0JIU2xfQVFkSFZpSzhpRy1kRkE1RGtHS2NKaE83SjZTX3lHc2lYRVZFVWsxeHdMNWlyaW94RzBTOWktdVZ4RUQ2RHBBMzNoVjc5MndYbGZZRjdyRGloUTVjRGdMcF9IR183ODZGSFpRamJqOHpRai13QkxKWElDeDh6Q3…
BBLG Q1 2026 Earnings: EPS Surprise Beats Estimates but Stock Declines as Pre‑Revenue Stage Continues - po-news-eg.net
<a href="https://news.google.com/rss/articles/CBMi3wFBVV95cUxQeUlQWUFVMUE5akFMX1Bzd1RMTFN2dkhrVDFpdVNQQVBIRk9EWUNiSmE4ejRCaXc2RmJaZE1NNTZpeDJTVzA5Q0VyOEEwOFZqa3BFVGdxMkFtZDZoSWxlTnNsMXQ4Y2daME00bmMwV244Rk1FOVZVcDlEMGY0bmVlZnlMbDNBeFpyaHFIcl…
BBLG — Frequently Asked Questions
What is the current share price of BBLG?
As of 2026-08-05 17:25 PDT, BBLG trades at $0.98 on NASDAQ/NYSE. Its 52-week range is $0.85 to $2.85.
What is the market capitalisation of BBLG?
BBLG has a market capitalisation of $1.76M on NASDAQ/NYSE.
What is the P/E ratio of BBLG?
BBLG trades at a trailing price-to-earnings (P/E) ratio of -0.37. Its price-to-book (P/B) ratio is 0.33.
What is the return on equity (ROE) of BBLG?
BBLG has a return on equity (ROE) of -57.81%. Its return on capital employed (ROCE) is -60.16%.
Is BBLG a good stock to buy?
This page provides a data-driven analysis of BBLG, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.